How to Use AI for a Hematology Practice in 2026: ASH Guidelines, Anticoagulation, MDS/AML, Sickle Cell, MIPS, HIPAA, and the Owner Scorecard
Published June 9, 2026 · 14 min read
The 7-Layer AI Stack for Modern Hematology Practices
| Layer | Purpose | Tools |
|---|---|---|
| Intake | Pre-visit + transfusion + chemo intake | Phreesia + NexHealth + Klara + Notable + Solv + Luma Health |
| Ambient SOAP | SOAP + E/M leveling + orders | DAX Copilot + DeepScribe + Abridge + Suki + Heidi + Freed + Augmedix + Sunoh.ai |
| EHR + PM | Charts + orders + billing + chemo | Epic Beacon + Cerner Oncology + athenahealth + iKnowMed + Flatiron OncoEMR + Varian + ARIA |
| Decision Support | NCCN + ASH + IPSS-M + MRD + trial match | Tempus + Caris + Foundation + Guardant + COTA + Concert AI + TrialJectory + Massive Bio |
| Prior-Auth | DOAC + biologic + cell-therapy appeal | CoverMyMeds + Glidian + Surescripts + Cohere + Banjo + Myndshft + AssistRx |
| Compliance | HIPAA + AKS + AI-scribe consent | Drata + Vanta + Compliancy + MedTrainer + HIPAA One + Keragon + SAFER |
| Outreach | Recall + reviews + survivorship | Weave + Solutionreach + Demandforce + Podium + BirdEye + NiceJob + Phreesia |
10 Copy-Paste Prompts for Hematology Practices
- AI pre-visit intake + transfusion history — Triage inbound for visit type (new + follow-up + chemo + transfusion + post-transplant + survivorship), HPI + B-symptoms scaffold, transfusion + chemo + radiation history, meds reconciliation + DDI flags, ECOG/KPS, family hx (HHT + thrombophilia + hemochromatosis + SCD trait), and ICD-10 tee-up.
- Ambient hematology SOAP — Generate SOAP with subjective + objective (CBC + CMP + LDH + uric acid + iron studies + flow + cytogenetics + FISH + NGS), assessment (ICD-10 C81-C96 + D45-D47 + D60-D64 + D69 + D70 + D75), plan (regimen + supportive care + transfusion threshold + growth factor + anticoagulation + trial referral), CPT 99202-99215 + 96365-96417 infusion + 38220/38221 BM bx + 99497-99498 ACP. Hematologist review required.
- Anticoagulation stewardship dashboard — For each patient on DOAC or warfarin, validate dose vs CrCl + indication (AF + VTE + CAT + mechanical valve) + DDI + bleeding risk (HAS-BLED + ATRIA + HEMORR2HAGES) per CHEST 2024 + ASH 2018 VTE + ASH 2021 cancer + ITAC 2022 + NCCN VTE 2026. Flag dose mismatches; auto-draft reversal protocol when needed.
- MDS + AML risk-stratification builder — From CBC + BM biopsy + cytogenetics + NGS, calculate IPSS-R + IPSS-M for MDS, ELN 2022 + 2024 update risk for AML + measurable residual disease eligibility. Cite NCCN AML/MDS 2026; output induction options (intensive vs venetoclax + azacitidine) + transplant eligibility per ASH/ASTCT consensus.
- MM staging + maintenance pathway — Apply R-ISS + R2-ISS staging from labs + cytogenetics + FISH; output quadruplet induction (Dara-VRd or Isa-VRd) candidacy, ASCT eligibility, lenalidomide maintenance dose + duration, MRD assessment timing per IMWG 2024. Cite NCCN MM 2026 + ASH 2024 updates.
- Sickle cell disease care plan — From genotype + organ-damage panel + transfusion hx, generate disease-modifying plan (hydroxyurea + L-glutamine + voxelotor + crizanlizumab + Casgevy/Lyfgenia eligibility per ASH 2020 + 2021 + FDA labels Dec 2023), VTE prophylaxis, vaccination, ACS workflow. Cite ASH SCD guidelines.
- Lymphoma + CLL workup pathway — From PET-CT + IHC + cytogenetics, generate Lugano staging for NHL/HL, iwCLL 2018 staging for CLL, CAR-T eligibility (axi-cel + liso-cel + brexu-cel + tisagenlecleucel) per NCCN NHL/CLL 2026. Output regimen options + clinical trial referral.
- VTE risk-stratification + treatment — Apply Wells + Geneva + PERC + YEARS for diagnosis; Caprini + Padua + IMPROVE for inpatient prophylaxis. Output anticoagulation duration (provoked vs unprovoked vs cancer-associated) per ASH 2020 + 2021 + ITAC 2022 + CHEST 2024. Flag thrombophilia workup criteria.
- State AI-scribe consent + HIPAA gating — For each new patient, surface state AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806) + FSMB Model Policy on AI 2024. Confirm BAA + minimum-necessary + access logs. Block ambient until consent captured.
- Owner monthly scorecard — Track visits/MD-day, infusion-chair utilization, MIPS MVP Advancing Cancer Care scores, trial enrollment rate, anticoagulation major-bleed + thromboembolism events, prior-auth turnaround + denial rate, AKS/Stark/Sunshine $13.46/$134.49 FY 2026 spend audit, OIG LEIE + GSA SAM.gov screen.
The 12-Item Hematology Compliance Floor
- HIPAA Privacy + Security + Breach Notification 45 CFR 160 + 164 + BAA with every AI vendor
- State medical-board scope + AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- NCCN Guidelines (AML, MDS, ALL, CLL, NHL, HL, MM, CML, MPN, VTE) + ASH evidence-based guidelines
- CMS E/M 2021+2023 + AMA CPT 2026 + ICD-10-CM Oct 1 2025 + chemotherapy administration coding
- MIPS MVP Advancing Cancer Care attestation accuracy (never invent measure compliance)
- FDA REMS for clozapine + thalidomide/lenalidomide + Casgevy/Lyfgenia + CAR-T programs
- Anticoagulation stewardship per CHEST 2024 + ASH 2018/2020/2021 + ITAC 2022 + NCCN VTE 2026
- USP General Chapter <797> + <800> hazardous drug compounding + handling
- AKS 42 USC §1320a-7b + Stark §1395nn + Sunshine $13.46/$134.49 FY 2026 spend log + 340B
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 $51,744/violation FY 2026
- TCPA 47 USC §227 + state mini-TCPA + FCC 2024 one-to-one + quiet hours 8am-9pm
- OIG LEIE + GSA SAM.gov exclusion screen + state Medicaid exclusion list (monthly)
60-Day Rollout Plan
Days 1-15: HIPAA + state AI-scribe consent audit; ambient SOAP pilot with one MD; anticoagulation stewardship baseline; MIPS MVP measure baseline.
Days 16-30: Roll ambient SOAP to all MDs; MDS/AML/MM risk-stratification dashboard live; prior-auth queue (DOAC + venetoclax + ibrutinib + lenalidomide + isatuximab + daratumumab + voxelotor + crizanlizumab + Casgevy/Lyfgenia).
Days 31-45: MIPS MVP gap-close sprint; clinical-trial matching live; SCD disease-modifying pathway; CAR-T referral pipeline.
Days 46-60: Owner scorecard live; AKS/Sunshine + 340B spend audit; FTC + TCPA refresh; OIG LEIE monthly screen; ACO + value-based contract reconciliation.
8 Mistakes That Kill Hematology AI Rollouts
- Auto-finalizing ambient SOAP without hematologist review (regimen + dose + ICD-10 errors)
- DOAC dosing without CrCl + DDI + bleeding-risk validation (major-bleed + thrombosis events)
- Treating AI MDS/AML risk score as ground truth without IPSS-M + ELN 2022 confirmation
- Inventing MIPS MVP Advancing Cancer Care attestations (CMS audit + clawback)
- Skipping state AI-scribe consent (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- Submitting CAR-T or Casgevy/Lyfgenia prior-auth without ASH/ASTCT-aligned eligibility
- Ignoring AKS/Stark/340B on AI vendor fee-splitting or referral-volume kickbacks
- Treating vendor AI dashboards as truth without validating against EHR + claims
Frequently Asked Questions
What is the single biggest 2026 AI risk for a hematology practice?
Two tied: (1) Anticoagulation stewardship errors — AI tools that auto-suggest DOAC dosing without integrating CrCl + drug-drug interactions + bleeding risk (HAS-BLED + ATRIA + HEMORR2HAGES) + indication-specific dosing (AF vs VTE vs cancer-associated thrombosis per CHEST 2024 + ASH 2018 VTE + ITAC 2022 + NCCN VTE 2026) trigger major bleeding + thromboembolism + state-board complaints. (2) MDS/AML/MM/lymphoma treatment-plan errors — AI clinical-decision tools that don't reconcile against current NCCN Guidelines (AML, MDS, ALL, CLL, NHL, HL, MM, CML, MPN), ASH evidence-based guidelines, IPSS-R + IPSS-M for MDS, ELN 2022 for AML, R-ISS + R2-ISS for MM trigger inappropriate regimen selection + missed clinical-trial referral + denied prior-auth + Medicare audit.
Can ambient AI scribes document hematology SOAP notes correctly?
Yes — DAX Copilot, DeepScribe, Abridge, Suki, Heidi, Freed, Sunoh.ai, Augmedix support ambient hematology SOAP with subjective (HPI + B-symptoms + PMH + transfusion history + chemo regimens + radiation + family hx + meds reconciliation), objective (vitals + LN/spleen exam + ECOG/KPS + CBC + CMP + LDH + uric acid + iron studies + B12 + folate + flow + cytogenetics + FISH + NGS), assessment (ICD-10 C81-C96 lymphoma/leukemia/MM + D45-D47 MPN + D60-D64 anemia + D69 platelet + D70 neutropenia + D75 RBC), plan (regimen + supportive care + transfusion threshold + growth factor + anticoagulation + clinical trial), and CPT 99202-99215 + 96365-96417 infusion + 38220/38221 BM bx + 96360 hydration + 99497-99498 ACP. Output requires hematologist review; never auto-finalize.
How does AI fit MIPS MVP reporting for hematology?
CMS finalized MIPS MVP Advancing Cancer Care for 2025 with continued refinement for 2026. Quality measures applicable include Q143 oncology cancer-stage documentation, Q144 medical-and-radiation-oncology pain assessment, Q104 prostate combined modality (overlap), Q047 advance-care plan, Q226 tobacco screening + cessation, Q134 depression screening, Q130 documentation of meds, Q110/Q111 immunization. AI helps via gap-list automation, pre-visit reconciliation, post-visit gap-close, and clean attestation accuracy. Documentation must match measure spec; never let AI invent attestations.
What hematology workflows benefit most from AI?
Anticoagulation stewardship (DOAC dosing per CrCl + DDI + indication; warfarin INR + sliding-scale; bridging with LMWH; cancer-associated thrombosis ITAC 2022 + ASH 2021); MDS/AML triage (IPSS-R/IPSS-M for MDS; ELN 2022 + 2024 update for AML risk + measurable residual disease; venetoclax + azacitidine vs intensive induction); MM staging + maintenance (R-ISS + R2-ISS; quadruplet induction + ASCT eligibility; lenalidomide maintenance + MRD); lymphoma + CLL pathway (NCCN NHL/HL/CLL; CAR-T eligibility per Lugano + iwCLL); sickle cell disease (ASH 2020 + 2021 SCD; voxelotor + crizanlizumab + L-glutamine + hydroxyurea + gene therapy Casgevy/Lyfgenia); ITP + TTP + HUS workflow; iron-overload chelation; venous-thromboembolism risk-stratification (Wells + Geneva + PERC + Padua + Caprini).
What is realistic ROI in 90 days?
Conservative targets: ambient SOAP rollout → 60-90 minutes/day saved per MD + 15-25 percent more visit slots; AI anticoagulation stewardship dashboard → 25-40 percent reduction in major bleeding + thromboembolism events; AI prior-auth + denial appeal (DOAC + venetoclax + ibrutinib + lenalidomide + isatuximab + daratumumab + voxelotor + crizanlizumab + Casgevy/Lyfgenia) → 20-30 percent denial-rate reduction; AI MIPS gap closure → 8-15 percentage-point lift on quality measures; AI patient messaging triage → 35-50 percent inbox-time reduction; AI clinical-trial matching → 2-4x increase in trial enrollment. Validate against EHR + claims + MIPS dashboards, not vendor self-reports.
Authoritative Sources
- ASH Clinical Practice Guidelines + ASH Education Book + Blood + Blood Advances
- NCCN Guidelines (AML, MDS, ALL, CLL, NHL, HL, MM, CML, MPN, VTE) 2026
- CMS E/M 2021+2023 office-visit guidelines + MIPS MVP Advancing Cancer Care 2026
- HIPAA Privacy + Security + Breach Notification 45 CFR 160 + 164
- State AI-scribe statutes (CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806)
- FSMB Model Policy on AI 2024 + FDA 510(k) + De Novo AI-SaMD list + REMS programs
- AKS 42 USC §1320a-7b + Stark §1395nn + Sunshine $13.46/$134.49 FY 2026 + 340B + AMA CPT 2026 + ICD-10-CM Oct 1 2025